Individualised dosimetry for holmium-166 RE in patients with unresectable hepatocellular carcinoma; a multi-centre, interventional, non-randomised, non-comparative, open label, phase II study: RHEPaiR

Authors

Rohini Sharma (ORCID: https://orcid.org/0000-0003-2441-549X)
María Carmen Riesco Martínez (ORCID: https://orcid.org/0000-0003-0626-0607)
Thomas Robert (ORCID: https://orcid.org/0000-0002-7580-0913)
Catherine Bowen (ORCID: https://orcid.org/0000-0002-7252-9515)
Maria Qurashi (ORCID: https://orcid.org/0000-0002-4821-4564)
Maarten L. J. Smits (ORCID: https://orcid.org/0000-0003-4735-655X)
Joep de Bruijne
Paul Tait (ORCID: https://orcid.org/0009-0009-2783-8069)
Caroline Ward (ORCID: https://orcid.org/0009-0006-3256-4515)
Marnix Lam
Sairah R. Khan (ORCID: https://orcid.org/0009-0007-8440-2216)
Hooshang Izadi
Charlotte Wyard

Institutions

Oxford Brookes University (GB)
University College London Hospitals NHS Foundation Trust (GB)
Utrecht University (NL)
Hammersmith Hospital (GB)
University Medical Center Utrecht (NL)
Netherlands Federation of University Medical Centres (NL)
University College London (GB)
Imperial College London (GB)

Publication Details

Journal: BMJ Open
Published: 2025-11-01
DOI: https://doi.org/10.1136/bmjopen-2024-097066
Primary Topic: Hepatocellular Carcinoma Treatment and Prognosis
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Gordon and Rose McAlpine Foundation for Neuroscience Research
Cancer Research UK
National Institute for Health and Care Research
Department of Health and Social Care
Imperial College London
NIHR Imperial Biomedical Research Centre

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Individualised dosimetry for holmium-166 RE in patients with unresectable hepatocellular carcinoma; a multi-centre, interventional, non-randomised, non-comparative, open label, phase II study: RHEPaiR

Rohini Sharma, María Carmen Riesco Martínez, Thomas Robert, Catherine Bowen et al.

Nov 1, 2025

BMJ Open

Hepatocellular Carcinoma Treatment and Prognosis

article

Individualised dosimetry for holmium-166 RE in patients with unresectable hepatocellular carcinoma; a multi-centre, interventional, non-randomised, non-comparative, open label, phase II study: RHEPaiR

Rohini Sharma, María Carmen Riesco Martínez, Thomas Robert, Catherine Bowen, Maria Qurashi, Maarten L. J. Smits, Joep de Bruijne, Paul Tait, Caroline Ward, Marnix Lam, Sairah R. Khan, Hooshang Izadi, Charlotte Wyard

November 1, 2025article en

Abstract

No abstract available for this paper.

BMJ OpenVol. 15(11)

Oxford Brookes University (GB), University College London Hospitals NHS Foundation Trust (GB), Utrecht University (NL), Hammersmith Hospital (GB), University Medical Center Utrecht (NL), Netherlands Federation of University Medical Centres (NL), University College London (GB), Imperial College London (GB)

Gordon and Rose McAlpine Foundation for Neuroscience Research, Cancer Research UK, National Institute for Health and Care Research, Department of Health and Social Care, Imperial College London, NIHR Imperial Biomedical Research Centre

Openalex Percentile: Top 54%

Hepatocellular Carcinoma Treatment and Prognosis

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Individualised dosimetry for holmium-166 RE in patients with unresectable hepatocellular carcinoma; a multi-centre, interventional, non-randomised, non-comparative, open label, phase II study: RHEPaiR — Rohini Sharma, María Carmen Riesco Martínez, et al. · BMJ Open (2025) | TGRS Research Map | TGRS